论文部分内容阅读
目的:探讨采用倍他乐克、通心络联合治疗冠心病心绞痛的临床效果。方法:选取2013年6月~2014年6月之间我院急诊的冠心病心绞痛患者200例,将其随机分为对照组与观察组,每组各100例,前者实施常规治疗,后者在此基础上联用倍他乐克和通心络治疗,比较临床疗效。结果:经过治疗,观察组心绞痛改善者占96.0%,高于对照组(62.0%),心电图改善者占92.0%,高于对照组(75.0%),差异显著,P<0.05。结论:采用倍他乐克、通心络联合治疗冠心病心绞痛,可以有效改善患者的心电图与心绞痛症状,而且安全性高,疗效理想。
Objective: To investigate the clinical efficacy of Betaloc and Tongxinluo in the treatment of angina pectoris. Methods: 200 patients with coronary heart disease and angina pectoris in our hospital from June 2013 to June 2014 were selected and randomly divided into control group and observation group, with 100 cases in each group. The former received routine treatment and the latter in control group Based on the combination of Betaloc and Tongxinluo treatment, the clinical efficacy. Results: After treatment, the improvement rate of angina in the observation group was 96.0%, higher than that of the control group (62.0%), the improvement of electrocardiogram was 92.0%, higher than that of the control group (75.0%), the difference was significant (P <0.05). Conclusion: The combination of Betaloc and Tongxinluo in the treatment of coronary heart disease angina pectoris can effectively improve the ECG and angina pectoris in patients with high safety and good curative effect.